Medistep Healthcare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹8(18.60%)
Premium (ELP)
Following its successful public offering, Medistep Healthcare Limited's made its market debut on Aug 18, 2025 and is now actively traded on the NSEplatform. The IPO mobilized 37,44,000 Shares in total capital, including 37,44,000 Shares in primary equity infusion.
The offering was structured with a price band of ₹43 to ₹43 and minimum investment lots of 3000 shares. Investor participation during the subscription window from Aug 08, 2025 to Aug 12, 2025 demonstrated market confidence in the company's prospects.
The allotment process concluded on Aug 13, 2025, allocating shares to successful bidders. The listing represents the culmination of the IPO process, transitioning the company to publicly traded status with enhanced transparency and governance standards.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Medistep Healthcare Limited, established in June 2023, is a pharmaceutical company involved in the production and trading of a variety of health and wellness products, including sanitary pads, energy powders, pharmaceutical and nutraceutical items, intimate care products, and surgical supplies. Focused on quality and growth, the company aims to expand its offerings as a public, non-government entity. As of December 30, 2024, it reported annualized revenue of ₹45 crore and a profit of ₹4.08 crore. The company had nine full-time employees, while additional labor needs are met through daily wage workers, with no contractual staff.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Leadership: Led by promoters with an experienced management team
- High Cost Savings: Achieves efficiency through large-scale production and streamlined supply chain
- Wide Product Range: Offers both in-house made and traded products in healthcare segments
- Regional Dependence: Heavy reliance on Gujarat market increases exposure to local risks
- Facility Dependency: Any disruption at the manufacturing unit can affect overall operations
- Supplier Reliance: Dependence on domestic third-party raw material suppliers may cause delays or shortages
- Girdhari Lal Prajapat
- Dabhi Vipul Gobarbhai
- Prajapati Hetalben Girdharilal
Medistep Healthcare Limited
Cameo Corporate Services Limited